REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies Meeting Abstract
| Authors: | Diab, A.; Marcondes, M.; Tagliaferri, M. A.; Hoch, U.; Zhang, J.; Rubas, W.; Kivimae, S.; Zalevsky, J.; Conley, A. P.; Borazanci, E.; D'Angelo, S. P. |
| Abstract Title: | REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy279.433 |
| Language: | English |
| ACCESSION: | WOS:000459277301030 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy279.433 |
| Notes: | Meeting Abstract: 446TiP -- Appears on pages viii146-viii147 of the abstract book -- Source: Wos |
